FDA Approves SEVENFACT, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitor

▴ FDA Logo
Haemophilia A or B inhibitor patients has a new hope

LFB today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) 2061 for SEVENFACT, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)-jncw], for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with Hemophilia A or B with inhibitors (neutralizing antibodies). An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.


Denis Delval LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the FDA approval of SEVENFACT® which provides a new treatment option for hemophilia patients. This approval is a validation of an innovative LFB technology. We will now work towards SEVENFACT registration in Europe and other core countries, in order to offer this therapeutic option to patients.”

Hemophilia A or B is a congenital bleeding disorder caused by a dysfunction or deficiency of Coagulation Factor (F) VIII or IX, respectively.

Tags : #Fda #Sevenfact #Newrecombinant #Coagulationfactor #Haemophilia #Haemophilia #Fdaapproval

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024
Empowering Patients: The Role of Advocacy in Indian HealthcareMarch 26, 2024
A New Dawn in Heart Surgery: Mitral Valve Repair for 15-Year-Old PatientMarch 26, 2024
Cracking the Code of Extended Fasting: Lessons from a Comprehensive InvestigationMarch 26, 2024
From Lab to Life: Exploring Eating Behaviors with AI WearablesMarch 26, 2024
Invisible Scars Foundation Hosts Disruptive Domestic Violence Stakeholder’s Summit (First Edition) in TelanganaMarch 23, 2024